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Abstract:  In the present review we have attempted to assess the involvement of the 
organic anion transporters OAT1, OAT2, OAT3, and OAT4, belonging to the SLC22 
family of polyspecific carriers, in drug-induced renal damage in humans. We have focused 
on drugs with widely recognized nephrotoxic potential, which have previously been 
reported to interact with OAT family members, and whose underlying pathogenic 
mechanism suggests the participation of tubular transport. Thus, only compounds generally 
believed to cause kidney injury either by means of direct tubular toxicity or crystal 
nephropathy have been considered. For each drug, or class of agents, the evidence for 
actual transport mediated by individual OATs under in vivo conditions is discussed. We 
have then examined their role in the context of other carriers present in the renal proximal 
tubule sharing certain substrates with OATs, as these are critical determinants of the overall 
contribution of OAT-dependent transport to intracellular accumulation and transepithelial 
drug secretion, and thus the impact it may have in drug-induced nephrotoxicity.  
Keywords:  drug-induced nephrotoxicity; tubular cell toxicity; nephrolithiasis; OAT1; 
OAT2; OAT3; OAT4 
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1. Specific Renal Vulnerability 
A variety of pathogenic mechanisms play a role in drug-induced nephrotoxicity, including 
hemodynamic changes, glomerular disease, interstitial nephritis, direct cytotoxicity which may result 
in tubular cell death, and intratubular precipitation of drugs leading to obstructive nephropathy [1–3]. 
High delivery of blood-borne substances, as well as concentration of xenobiotics entering the tubular 
lumen in the course of their tubular passage, in particular under conditions of dehydration, contribute 
to the particular vulnerability of the kidneys to injury by clinically relevant drugs, as well as 
environmental toxins. A large number of secretory transporters in the renal proximal tubule, many of 
them polyspecific, contribute not only to high intratubular solute concentrations, but also to exposure 
of the tubular epithelium to high intracellular levels of potential cytotoxins. The latter may be further 
aggravated for compounds which are additionally reabsorbed from the tubular fluid. High metabolic 
activity may in part account for the sensitivity of proximal tubule cells to damage by such agents 
known to interfere with mitochondrial substrate utilization or to decrease cellular antioxidant capacity. 
Several organic anion transporters (OATs) of the SLC22 family of solute carriers, many of which 
accept a markedly broad spectrum of substrates, are present on either side of the renal proximal tubular 
epithelium. There, OAT-mediated transport can contribute to two types of renal injury: (i) direct 
cellular toxicity by allowing access of damaging agents such as antiviral drugs to the cytosol, as well 
as (ii) crystal nephropathy by mediating transepithelial secretion of compounds with low solubility in 
urine that tend to precipitate upon urinary concentration, such as methotrexate or acyclovir [4]. In the 
present review, we have focused on selected OAT drug substrates, for which clinically relevant 
tubulotoxicity and/or nephrolithiasis have been reported, and have attempted to assess the contribution 
of individual OATs to these processes in the context of additional proximal tubular transport pathways 
for the respective compounds. We have thus limited ourselves to those OAT family members known to 
interact with the nephrotoxic pharmaceuticals discussed. For a more comprehensive overview of the 
pharmacological, as well as physiological, relevance of SLC22 organic anion transporters, the 
interested reader is referred to the excellent extensive reviews by Sweet [5], Rizwan and Burckhardt [6], 
and van Wert et al. [7].  
2. Involvement of OATs in Renal Proximal Tubular Solute Uptake and Transepithelial Secretion 
In humans, OAT1 (SLC22A6), OAT2 (SLC22A7) and OAT3 (SLC22A8) are present in the 
basolateral membrane of renal proximal tubule cells [8–11]. OAT1 and OAT3 operate as exchangers 
for intracellular dicarboxylate [12–14], originating mainly from basolateral import via Na
+-driven 
uptake mediated by NaDC-3 as well as cellular metabolism, while uptake of dicarboxylate from the 
tubular lumen—at least in the rabbit—appears to play only a minor role in the energetics of   
OAT1- and OAT3-mediated transport [15]. In rat renal cortical tissue, the concentration of   
-ketoglutarate (-KG) as the most likely endogenous dicarboxylate exchanging for extracellular 
organic anions via OAT1 and OAT3 [16] has been estimated to be in the range of 265 µM [17], and 
the affinity of overall basolateral transport in rat renal basolateral membrane vesicles, mediated by 
both Oat1 and Oat3 is in the range of 150 µM [17]. The affinity of human OAT1 for the   
non-metabolizable analogue glutarate is high, with a Km of about 11 µM [18]. Thus, both OAT1 and 
OAT3 are likely to mediate influx of drugs into renal proximal tubular cells under in vivo conditions, Toxins 2010, 2  
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even if not all of the cellular dicarboxylate may be readily available for exchange [17]. The mRNA 
expression level of hOAT3 is almost 3-fold higher than that of hOAT1 [8]. If this difference were to 
translate into corresponding differences at the protein level, hOAT3 would be expected to predominate 
in the basolateral uptake of substrates for which hOAT1 and hOAT3 show similar affinities and 
turnover rates, and may still contribute significantly to the influx of compounds preferentially 
transported by hOAT1. 
Figure 1. Human transporters involved in proximal tubular handling of nephrotoxic drugs 
discussed in the present review. OAT family members are shown in orange and yellow, 
ATP-driven pumps in green, all other carriers in blue. OA
−: organic anion;   
-KG:  -ketoglutarate; MTX: methotrexate; OAT: organic anion transporter;   
MRP: multidrug resistance-associated protein; PEPT: peptide transporter; OCTN2: novel 
organic cation transporter type 2; PCFT: proton-coupled folate transporter;   
MATE: multidrug and toxin extrusion protein; OATP: organic anion-transporting 
polypeptide; RFC: reduced folate carrier. 
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While hOAT2 has also been reported to transport -KG and glutarate [19,20], hOAT2-mediated 
organic anion exchange for dicarboxylates has never been convincingly demonstrated. Thus, hOAT2 
may be more likely to function as an efflux mechanism for anionic solutes reabsorbed from the tubular 
lumen, but could also constitute a back-leak pathway into the circulation for substrates shared with 
OAT1 and/or OAT3, such as methotrexate or, possibly, cephalosporin antibiotics. OAT2 mRNA 
expression in the human renal cortex, however, amounts to less than 15% of that determined for 
hOAT1 [8], and its overall contribution to proximal tubular organic anion handling may therefore 
be limited. 
OAT4 (SLC22A11), localized at the apical side of the proximal tubule cells, is known to function 
as an exchanger for dicarboxylates, albeit with a low glutarate affinity (IC50 value 1.25 mM, 
determined at a substrate concentration of 50 nM)[21]. Thus, depending in part on its affinity relative 
to OAT1 and OAT3 for a given compound, OAT4 may either contribute to its cellular accumulation by 
uptake from the tubular fluid, or mediate luminal efflux in the process of transepithelial secretion. 
However, hOAT4 has been shown to be asymmetric in function at least for some substrates, promoting 
efflux but not uptake of glutarate and PAH [22]. While this would challenge the importance of OAT4 
in mediating direct tubular cytotoxicity, it is unclear at present whether outwardly directed transport 
also predominates for other substrates. Nevertheless, mRNA expression of OAT4 in human kidney 
cortex is even lower than that of OAT2 [8], suggesting a minor involvement in drug-induced 
nephrotoxicity also for this carrier. 
All four OATs mentionened above are sensitive to inhibition by the classical organic anion 
transport inhibitor probenecid, albeit with different affinities. While Ki or IC50 values in the range of 
4.3–12.5 µM and 4–9 µM have been determined for hOAT1 and hOAT3, respectively, the affinity was 
determined to be somewhat lower for hOAT4 (44–68 µM), and even less for hOAT2 (766 µM)[6,23]. 
Probenecid has been frequently used to verify a secretory component in the renal elimination of a 
certain anionic drug (see below). However, it has to be emphasized that MRP and possibly also OATP 
family members present in the renal tubule epithelium are likewise probenecid-sensitive [24,25]. 
3. Direct Proximal Tubular Toxicity of OAT Drug Substrates 
Several drugs as well as some components of Chinese herbal medications reported to be directly 
toxic to proximal tubule cells, including several antivirals, ß-lactam antibiotics, or aristolochic acid, 
are well-known substrates of OATs, the most extensively characterized basolateral uptake carriers 
OAT1 and/or OAT3 in particular. Yet, cytotoxicity of a certain agent in vivo also critically depends on 
the presence and activity of additional transport pathways, most notably those mediating apical efflux. 
3.1. ß-Lactam antibiotics 
Among the ß-lactam antibiotics, many synthetic compounds of the cephalosporin and even more so 
of the penem group, developed for a broader antimicrobial spectrum and bactericidal potency, have 
turned out to be highly nephrotoxic, in some instances to an extent prohibiting their clinical use.  
ß-Lactam-induced tubular necrosis has been attributed mainly to impaired import and oxidation of 
monocarboxylate substrates by mitochondria, as well as to cellular antioxidant depletion and lipid 
peroxidation [26,27]. Most cephalosporins are excreted to a significant fraction or even predominantly Toxins 2010, 2  
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via the kidneys in humans [28,29]. Renal elimination of many cephalosporins, including cefaclor, 
cezolin and cephalothin, was significantly attenuated by coadministration of probenecid, indicating a 
contribution of tubular secretion via the organic anion pathway [30].  
A number of cephalosporins, including cephaloridine as one of the most toxic [31], have been 
shown to significantly inhibit human OAT1, OAT2, OAT3, as well as OAT4 [32–34](Table 1). 
Although IC50 values determined in one study suggested that relative to hOAT1, heterologously 
expressed hOAT3 may be more sensitive to inhibition by most cephalosporins tested, data for hOAT1 
and hOAT3 were not directly comparable, as they were obtained at a 250-fold higher substrate 
concentration for hOAT1 than for hOAT3 [34]. Conversely, according to the Ki values reported by 
Takeda  et al., hOAT1 actually exhibited the stronger affinity for the majority of cephalosporins 
assayed, including cephaloridine [32]. Yet, Ueo et al. demonstrated that heterologous expression of 
hOAT3 induces significant uptake, typically several fold above control (approx. 30-fold for 
cephaloridine), of all cephalosporins included in their study, whereas hOAT1-dependent uptake was 
low (e.g., cephaloridine) or non-significant (e.g., cefaclor or cefazolin)[34]. These data suggest a 
considerably more important role of hOAT3 over hOAT1 in tubular cephalosporin uptake, even if 
transporter-induced probenecid-inhibitable cephaloridine toxicity was found to be similar for both 
hOAT1 and hOAT3 in a different expression system [32]. The reason for this discrepancy is unclear, 
but might be related to differences in expression levels and/or the long incubation time (24 h) in the 
latter report. In this context, it is interesting to note that while the level of overexpression of hOAT3 
was determined to be about 3-fold higher than that of hOAT1 in the HEK293 cells as used by 
Ueo et al. [34], this actually more closely reflects the situation in the human renal proximal tubule, as 
indicated above. 
In contrast, although mouse proximal tubule cells stably transfected with hOAT2 or hOAT4, like 
those expressing hOAT1 and hOAT3, displayed increased sensitivity to cephaloridine toxicity, they 
differed it that cell viability was not significantly enhanced or only marginally affected by the 
simultaneous presence of probenecid, respectively [33]. While for hOAT2 this result was attributed to 
the transporter's low probenecid affinity, no such explanation can account for the low responsiveness 
of hOAT4. At present, it therefore appears unlikely that OAT4 plays a role in cephaloridine toxicity, or 
in its transepithelial secretion, whereas OAT2 may constitute a back-leak pathway of cephalosporins 
into the blood. 
Many cephalosporins are well-known substrates of the proton-coupled peptide transporters hPEPT2 
and hPEPT1, localized at the apical membrane of the renal proximal tubule epithelium. Of the 
nephrotoxic cephalosporins known as OAT substrates, the aminocephalosporin cefaclor is also 
transported with high affinity by PEPT2, while the affinity for PEPT1 is low, although transport has 
been demonstrated. On the other hand, there is at best weak interaction of either carrier with 
cephaloridine and cefalothin, as these lack a free amino group [35–37]. In contrast, OCTN2, another 
carrier localized at the apical membrane of tubule cells [38], has been shown to be highly sensitive to 
inhibition by cephaloridine, as well as by a number of other cephalosporins [37]. Yet, conflicting 
results have been reported as for its ability to actually translocate cephaloridine [37,39]. Interestingly, 
however, in mice Octn2 has recently been associated with Na-independent apical cephaloridine 
extrusion into the tubular lumen, rather than cellular uptake [40]. Toxins 2010, 2  
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Table 1. Interaction of drugs known to be directly toxic to proximal tubule cells with 
human renal OATs and other human proximal tubular transporters. All values are in µM. 
T: transport demonstrated; n.t.: not transported; I: inhibition shown; n.i.: no inhibition;  
*: Km; 
: Ki; 
: IC50; 
a: carrier-induced toxicity of compound (CC50, concentration inducing  
half-maximal toxicity); 
b: no transporter-mediated toxicity; 
c: carrier-induced resistance;  
d: value determined in the absence of serum. 
Substrate OAT1  OAT2  OAT3  OAT4 
Other Transporters 
References 
MRP2 MRP4  Additional  Carriers 
-Lactam Antibiotics 
Cefaclor n.t.; 
1096     T; 
120      I   PEPT2: *70.2; 
65
 
PEPT1: T, 
4520; 
~11000 
[34,36,41,42] 
Cefazolin n.t.; 
101 
5090
  T; 
117   n.t.
  *81   [29,33,34,42] 
Cephaloridine T; 
aT; 
740; 
2470; 
1250
 
aT; 
2090 
T; 
aT; 
2460; 
626 
aT; 
3630 
 n.i.  PEPT2:  n.i.; 
PEPT1: n.i.; 
OCTN2: T; 
790; n.t. 
 
[18,32–34,36, 
37,39,42] 
Cephalothin 
220  
1040  
40  
200     I   PEPT2: 
7500; PEPT1: 
14000  
[32,33,35,36,42] 
Imipenem 
bn.t.    
aT (770)         [43] 
Meropenem T    *847         [44] 
Antivirals 
Adefovir *23.8;  *30    *1220
     n.t.   * >1 mM; 
cT
   [12,18,45–47] 
Cidofovir  *46; *58        n.t.   n.t.    [12,46–48] 
Tenofovir *33.8   *770    n.t.
  * >1 mM; T    [45,46,49] 
NSAIDs  
Acetylsalicylate 
769 
 >2000 
717 
 >2000        [50] 
Ibuprofen 
55.6 
692 
6.00; 
,d1170 
103 
930 
26.3; I
   [50–53] 
Mefenamic acid 
0.83 
21.7 
0.78 
61.7       [50] 
Phenacetin 
275 
1878 
19.4 
 >2000        [50] 
Phenylbutazone 
   ,d34.7 
  605 
130   [51,52] 
Aristolochic 
acid 
0.6
   
0.5 
20.6       [54] 
Both MRP2 and MRP4 seem to constitute luminal efflux pathways for at least some ß-lactam 
antibiotics, including cefazolin (MRP4 only), in the human renal proximal tubule [29,42,55], with 
apparent affinities in the micromolar range determined for MRP4-mediated transport of ceftizoxime 
and cefazolin (Table 1). Moreover, most cephalosporins tested dose-dependently inhibited   
MRP4-mediated transport, with the notable exception of cephaloridine [42]. This is consistent with the 
finding in rabbits that cephaloridine exhibits only minimal efflux into the tubular fluid, which may 
explain its particularly high nephrotoxicity [26,56]. Interaction of cephaloridine with MRP2 has not 
been tested. Whether human NPT1 is also able to mediate Na
+-independent transport of ß-lactam 
antibiotics and thus contributes to their apical secretion, as reported for its mouse orthologue [57], 
remains to be determined. Toxins 2010, 2  
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In contrast to cephalosporins, literature regarding the renal transport of penems in humans is scarce. 
Imipenem, which has been shown to cause tubular necrosis in experimental animals [58,59], is used in 
severe polymicrobial infections and sepsis. Imipenem is eliminated primarily via the kidneys, and 
probenecid has been found to slightly, but significantly retard its excretion [60,61]. Lim et al. recently 
reported that expression of hOAT3, but not hOAT1, in MDCK cells induced sensitivity to imipenem 
toxicity with a half-maximal effect at sub-millimolar imipenem concentrations [43]. However, 
imipenem is commonly administered together with cilastin, which not only inhibits its degradation by 
the renal dehydropeptidase I, but also prevents its nephrotoxic effect [58]. Interestingly, in vitro, 
cilastin has been found to preferentially inhibit hOAT3 (Ki 231 µM) over hOAT1 (Ki 1470 µM)[62]. 
Likewise, panipenem, which is similarly nephrotoxic [26], is marketed as a combination drug with 
betamipron [63], which has been found to largely prevent panipenem nephrotoxicity in rabbits [64]. 
Betamipron is a potent inhibitor of both hOAT1- and hOAT3-mediated transport (Ki values of 23.6 and 
48.3 µM, respectively), whereas hOAT4 is somewhat less affected (Ki 502 µM)[11,62]. In contrast to 
imipenem, meropenem, reported to be only mildly nephrotoxic toxic in rabbits and monkeys [65], was 
found to be a substrate of both hOAT1 and hOAT3 [44]. 
Taken together, OAT3, possibly complemented to some extent by OAT1, currently appears to be 
the predominant uptake pathway for those nephrotoxic ß-lactam antibiotics not belonging to the 
amino-ß-lactams, as well as for several carbapenems, into human renal proximal tubule cells. In 
contrast, the mechanisms mediating apical efflux, albeit apparently limited for some of these drugs, are 
less clearly defined. While MRP2 and MRP4 interact at least with some of the moderately (or non-) 
toxic cephalosporins, data regarding their interaction with carbapenems are lacking, and the potential 
contribution of OCTN2 does not seem to be fully elucidated. 
3.2. Antiviral drugs 
The treatment of severe viral infections often requires long-term drug therapy, which unfortunately 
is frequently associated with severe side-effects. Clinically relevant nephrotoxic adverse effects of 
antiviral compounds are well documented in the literature, as reviewed in [66]. Dose-limiting direct 
tubular toxicity has been reported in particular for the nucleotide analogues adefovir and cidofovir, 
used primarily for treatment of infections with DNA viruses, such as cytomegalovirus or hepatitis B 
virus [67–71]. Adefovir and cidofovir are mainly eliminated unchanged via the kidneys by a 
combination of glomerular filtration and tubular secretion, with secretion contributing about 60% and 
35% to the renal clearance of adefovir and cidofovir, respectively [72,73]. Adefovir-induced cellular 
damage has been attributed to mitochondrial injury, impaired ATP synthesis and/or interference with 
ATP-dependent cellular mechanisms [74]. Cidofovir is believed to be toxic due to interference with 
cellular lipid synthesis and/or degradation [74]. Adefovir and cidofovir have both been shown to be 
high affinity substrates of hOAT1 [12,48], whereas they were found to be only marginally transported 
by hOAT3 in some studies (adefovir [75], cidofovir [76]). At least with respect to adefovir, this 
finding might be explained by an affinity for hOAT3 about 50-fold lower than for hOAT1 [45]. To our 
knowledge there are as yet no reports on the ability of hOAT2 and hOAT4—as potential efflux routes 
from proximal tubular cells—to interact with nucleotide analogue antivirals. Toxins 2010, 2  
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In contrast, MRP4 is well known to be able to transport adefovir, but not cidofovir [46,47], whereas 
MRP2 does not seem to be involved in the apical extrusion of nucleotide analogues [46]. Interestingly, 
the nucleotide analogue tenofovir, used in particular for the treatment of HIV infections, has originally 
been considered relatively safe, when compared to adefovir and cidofovir, with no evidence for tubular 
toxicity observed in earlier clinical trials [77,78]. Yet, similar to adefovir and cidofovir, tenofovir, 
which is also negatively charged under physiological conditions, is a high affinity substrate of hOAT1, 
albeit a rather poor substrate for hOAT3 with a high-micromolar Km value [45]. Transport efficiency 
via hOAT1—determined in the same expression system under identical conditions—was even almost 
twice that of adefovir and cidofovir [45]. Transport via MRP4 as a possible apical efflux route 
displayed an affinity for tenofovir as low as for adefovir [46], while again no MRP2-mediated 
transport was observed [46,49]. Thus, the generally lower nephrotoxicity of tenofovir relative to 
adefovir or cidofovir at present does not seem to be attributable to differences in tubular transport, 
suggesting that higher cytosolic concentrations—as could result from impaired luminal efflux (see 
below)—might be required for tenofovir to cause cellular injury. Indeed, tenofovir has been shown to 
have a relatively low toxicity toward mitochondria [79]. 
More recently, however, an appreciable number of cases of tenofovir-induced Fanconi-like 
syndromes and acute renal failure have been reported, in part under combination therapy with HIV 
protease inhibitors, such as lopinavir/ritonavir or atazanavir [80–83]. These renal adverse effects have 
alternatively been associated with MRP2 polymorphisms, such as the V417I variant [84], or attributed 
to an interaction of the protease inhibitor with MRP2- or MRP4-mediated export [66,85,86]. The 
reason for the association of tenofovir-induced proximal tubular damage with the MRP2-V417I variant 
is as yet unclear. Although MRP2-mediated tenofovir transport might have escaped detection if MRP2 
exhibited an even lower affinity for this antiviral drug than MRP4, in vitro MRP2-V417I did not differ 
functionally from wildtype-MRP2 [87], but tenofovir was not tested. At least on the mRNA level, also 
no correlation between the corresponding 1249G > A polymorphism and MRP2 expression could be 
detected in normal kidney [88]. On the other hand, a possible interference of ritonavir, lopinavir and 
atazanavir with MRP4-/MRP2-mediated tenofovir efflux is not supported by certain in vitro data 
showing that none of these protease inhibitors aggravated tenofovir-induced cytotoxicity in hMRP2- or 
hMRP4-overexpressing MDCK cells, indicating a lack of interaction with these carriers. However, at 
least in the absence of serum, ritonavir did indeed significantly inhibit tenofovir efflux from   
hMRP4-HEK293T cells [89]. Based on their results, the latter authors attributed tenofovir nephrotoxicity 
in the context of highly active antiretroviral therapy (HAART) to drug-drug interactions at the level of 
hepatic transport and/or metabolism. Yet, given that tenofovir has been reported to be predominantly 
eliminated unchanged via the kidneys through filtration and secretion [90] and that impaired liver 
function was not found to alter tenofovir disposition [91], this assumption may not be correct, 
especially since ritonavir has indeed been shown to retard renal tenofovir elimination [92]. 
So far, data on interaction of the nucleoside phosphonate antivirals mentioned, as well as protease 
inhibitors, with human OATs other than OAT1 and OAT3, notably the apical OAT4, are lacking. This 
would be of particular interest as to better understand both the luminal efflux step not only for tenofovir, 
but also cidofovir (see above), as well as to identify potential targets for antiviral drug interactions. 
 Toxins 2010, 2  
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3.3. Non-steroidal anti-inflammatory drugs 
Nephrotoxicity induced by non-steroidal anti-inflammatory drugs (NSAIDs), many of which are 
known to interact with human OATs (recently reviewed in [6]), has frequently been reported [3,93]. 
However, in contrast to the early study by Muhalwas [94], renal adverse effects of NSAIDs have 
mostly been attributed to causes other than direct proximal tubular toxicity, such as hemodynamic 
changes due to inhibition of prostaglandin synthesis [93,95], allergic interstitial nephritis [96,97], or 
papillary necrosis [98]. Moreover, Rosenberger and co-workers have suggested that ischemia may 
contribute even to kidney injury primarily ascribed to direct tubulotoxicity [95]. Similarly, as pointed 
out by Silva, it is often difficult to establish whether tubular epithelial damage may be secondary to 
interstitial nephritis or is the primary event [99]. 
Although nephrotoxicity of NSAIDs is low when taken at therapeutic doses over short periods of 
time, NSAID-induced nephropathy presenting with papillary rather than proximal tubular damage has 
frequently been observed as a result of abusive NSAID consumption, or when renal perfusion was 
compromised [98,100]. Thus, NSAID-induced chronic and/or acute renal papillary necrosis has been 
reported for phenacetin, acetylsalicylate, fenoprofen, mefenamic acid, ibuprofen, and phenybutazone 
[98,100], several of which most potently interact with hOAT1 and/or hOAT3, while higher 
concentrations were found to also inhibit hOAT2 and hOAT4 (Table 1). 
At least for the excessive use of phenacetin (or its active metabolite acetaminophen) in combination 
with aspirin, papillary necrosis has been established as the primary event [99]. Toxic free radicals 
resulting from acetaminophen metabolism are postulated to be the cytotoxic agents, and aggravation of 
the damage by salicylates appears to result from glutathione depletion [99,101], rather than drug-drug 
interactions at sites of renal transport. Interestingly, acetaminophen, acetylsalicylate and salicylate 
have all been found to be directly toxic to mouse inner-medullary collecting duct cells in culture, and 
cyclooxygenase inhibition alone could not account for this effect [102]. Since high doses of drugs are 
required to induce these effects, proximal tubular secretion followed by intratubular concentration may 
well contribute to the selective papillary damage. Although, to the best of our knowledge, actual 
transport of NSAIDs by members of the OAT family of carriers has never been demonstrated, potent 
inhibition of the basolateral exchangers OAT1 and OAT3, in particular, by a variety NSAIDs may 
implicate these transporters in their trans-tubular secretion [50,51](Table 1). 
In this context it is interesting to note that phenacetin, a potent inhibitor of hOAT3, had been 
removed from the market by 1999, owing to its nephrotoxicity, whereas its metabolite acetaminophen, 
which only appears to interact rather weakly with hOAT1, has been reported not to be toxic to the 
kidney when taken at therapeutic doses [98].  
Apical export of NSAIDs might be mediated by MRP2 and MRP4, which have been shown to be 
inhibited by a variety of NSAIDs, including ibuprofen and phenylbutazone [52,53,103](Table 1). 
Inhibitory potency was typically higher toward MRP4 than toward MRP2 [52]. That NSAIDs can 
indeed function as substrates of MRPs has for example been demonstrated by increased   
MRP2-ATPase activity in the presence of indomethacin [103]. OAT4, which is substantially more 
sensitive to inhibition by most NSAIDs tested than the basolateral OAT2 [50], represents an additional 
candidate efflux pathway into the tubular lumen. Toxins 2010, 2  
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3.4. Aristolochic acid 
In 1992, two female patients were admitted to hospitals in Brussels (Belgium), with severe 
interstitial nephritis, resulting in terminal renal failure within a relatively short period of time. This 
rapidly progressing nephropathy could only be attributed to the slimming pills both women had been 
taking for a period of more than a year. Subsequently, it was suspected that in the medication 
containing herbs used in traditional Chinese medicine, Stephania tetrandra had probably inadvertently 
been replaced by Aristolochia fangchi, which  contains aristolochic acid (AA)[104,105]. The 
nephrotoxic action of AA in humans had already been described in 1964 by Jackson and coworkers 
[106]. Despite the resulting ban of Stephania tetrandra from the Belgian market by the end of 1992, 
more than 100 cases of Chinese-herb nephropathy (CHN) were reported in Belgium in 1998 alone [107].  
Several in vivo and in vitro experiments indicated that the main targets of AA are the proximal 
tubule cells. The histological hallmark of CHN detected in kidney biopsies of patients was proximal 
tubular atrophy. Lesions of this type of nephropathy were primarily found in the superficial cortex, the 
renal zone with a very high density of proximal tubules, subsequently progressing into deeper cortical 
regions [108]. Quantification of the activity of neutral endopeptidase (NEP), a marker enzyme of the 
proximal tubular brush border membrane, in urine of patients in earlier stages of the nephropathy, and 
in patients with severe renal failure (end-stage) due to AA administration revealed a 45% and 90% 
reduction of the NEP activity, respectively, compared to healthy control subjects. NEP is excreted in 
urine under physiological conditions and is taken as measure for the amount of renal enzyme [109]. 
Treatment of rabbits and rats with AA was found to result in flattening of the proximal tubular 
epithelium, as well as to severe tubular atrophy [110]. In rats, AA-induced tubular atrophy and 
development of interstitial fibrosis could be attributed to epithelial mesenchymal transformation 
(EMT). This was evidenced by a decrease in N- and E-cadherin expression, and a concomitant 
increase in the mesenchymal marker vimentin as well as the myofibroblast protein alpha-smooth 
muscle actin [111]. Consistent with the hypothesis that contamination with AA, known for its 
carcinogenic potential, was the underlying cause of CHN, both pure AA as well as the herbal mixture 
contained in the slimming medication induced tumors in rats [112]. Moreover, AA-specific DNA 
adducts could be detected in kidney samples of CHN patients [113]. AA-induced DNA adduct 
formation may be causally related to the morphological changes seen in renal tissue from CHN 
patients, as AA-treated opossum kidney (OK) cells were found to have reduced megalin surface 
expression and were positive for AA-related DNA adducts [114]. 
OK cells are not only a well established proximal tubule cell model for studies of the   
megalin-/cubilin-mediated endocytosis, but have also been documented to express critical components 
of the organic anion secretory pathway, thus exhibiting probenecid-sensitive intracellular accumulation 
as well as basolateral-to-apical transcellular flux of model organic anions such as -aminohippurate 
[115]. As AA is an organic anion, its entry into the cells in the studies by Lebeau et al. might have 
been OAT-mediated [114]. Recently, Bakhiya et al. indeed demonstrated potent inhibition of hOAT1, 
hOAT3 and hOAT4 expressed in HEK293 cells by aristolochic acid I (AAI) with Ki values of 0.6, 0.5, 
and 20 µM, respectively [54]. Moreover, upon AA treatment, significantly higher levels of   
AA-specific DNA adducts were detected in all hOAT-overexpressing cells than in controls, an effect 
which could abolished by the presence of probenecid during the incubation with AA. Toxins 2010, 2  
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The preferential damage of proximal tubule cells in AA nephropathy may thus be due to   
hOAT1-/hOAT3-mediated cellular AA accumulation. Given its asymmetric operation, it remains to be 
determined whether hOAT4 can function as an apical efflux pathway for AA, or may rather aggravate 
cellular injury by mediating additional uptake from the tubular fluid. As yet, the role of hOAT2, as 
well as of MRP2 and MRP4 in the proximal tubular handling of AA and thus their potential impact on 
the progression of AA-induced nephropathy has not been resolved.  
4. Nephrolithiasis 
Drug-induced nephrolithiasis in general appears to be a relatively rare event [116]. Nevertheless, a 
number of drugs known to interact with OAT-type transporters, including methotrexate, some 
antibiotics and certain antiviral therapeutics, have been more frequently associated with acute kidney 
injury due to intratubular crystal formation [2,4]. Risk factors include dehydration, metabolic changes 
affecting urinary pH, as well as, at least with respect to some compounds, calciuria (see below). 
4.1. Methotrexate 
Methotrexate (MTX) is used in the management of certain types of cancer as well as several   
auto-immune diseases, such as rheumatoid arthritis, inflammatory bowel disease or systemic lupus 
erythematodes [117–120]. For the treatment of malignancies in both adults and children, high-dose 
methotrexate is frequently used [121]. However, a number of sometimes fatal cases of MTX-induced 
acute renal failure have been reported, especially upon co-administration with NSAIDs, such as 
indomethacin and ketoprofen [122–125]. As stated by Widemann and Adamson in 2006,   
MTX-induced nephrotoxicity still occurs, albeit infrequently [121]. MTX-induced renal impairment 
appears to be primarily due to the precipitation of MTX and its metabolites in the tubular lumen, 
although direct tubular toxicity due to compromised apical MTX efflux has also been reported 
[4,121,126]. MTX is excreted mostly unchanged via the kidneys and renal elimination appears to be a 
function of both secretion as well as reabsorption [127,128]. As the solubility of MTX is low at acidic 
pH values, metabolic changes resulting in increased tubular acidification constitute a further risk factor 
in addition to high dosage.  
hOAT3 has been shown to be a high-affinity transporter for MTX uptake into renal proximal tubule 
cells [10,129], whereas hOAT1 was initially reported not to accept MTX as a substrate [13](Table 2). 
However, the failure to detect hOAT1-mediated MTX transport in the latter study might have been due 
to the low concentration (0.2 µM) used, since hOAT1 was later shown to have a low MTX affinity  
(Km 554 µM/724 µM [51,129]). Thus, hOAT1 may well contribute significantly to basolateral MTX 
uptake into renal proximal tubule under high-dose methotrexate administration as used in cancer 
therapy, resulting in mean peak MTX plasma concentrations of 1mM and above have been determined 
[130]. As yet, it is unclear if any back-leak of MTX into the circulation via hOAT2 can be completely 
excluded, as the inability of this carrier to mediate MTX flux has so far only been indicated in one 
report, referring to unpublished data with no indication of the concentration applied [51]. Toxins 2010, 2  
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Table 2. Interaction of drugs associated with nephrolithiasis with human renal OATs and 
other proximal tubular transporters. All values are in µM. T: transport demonstrated;   
n.t.: not transported; I: inhibition shown; n.i.: no inhibition; *: Km; 
: Ki; 
: IC50; 
a: referral 
to unpublished data in [51]. 
Substrate OAT1  OAT2  OAT3  OAT4 
Other Transporters 
References 
MRP2 MRP4  Additional  Carriers 
Cytostatics 
methotrexate 
(MTX) 
*724; 
*554; 
n.t.
 
an.t.; T  *17.2; 
*10.9; 
*21.1 
*17.8 *2500–3000; 
*250; *480 
*220; 
*220; 
*1300 
hOATP4C1: T 
 
[10,13,19,51,52, 
103,129,131–134] 
ß-Lactam Antibiotics 
Ceftriaxone 
230 
6760 
  4390  
2380  T     PEPT1: n.i.  [29,32,33,36] 
Carboxyfluoroquinolones 
Ciprofloxacin n.i. 
   I 
      MATE1:  n.t.; 
231; 
MATE2-K: n.t.; 
98.7 
[135,136] 
Antivirals 
Acyclovir  *342 n.i.
  n.t.; I  n.i.
     MATE1:  *2640; 
MATE2-K: *4320  
[136,137] 
Reduced-folate carrier 1 (RFC1), known to be expressed basolaterally in mouse renal tubules [138], 
likely complements OAT3 (and OAT1) in contraluminal MTX uptake also in the human kidney, as 
hRFC expression induces MTX uptake and confers MTX sensitivity to MTX-resistant cells [139,140]. 
In rat renal cortical slices, RFC and Oat3 contributed about equally (approx. 30% and 30–50%, 
respectively) to MTX-uptake at a low concentration (500 nM), with Oat1 playing only a minor role 
[141]. As a further basolateral MTX transporter potentially contributing to the uptake step in renal 
MTX secretion, hOATP4C1 has been identified [134]. 
Luminal MTX efflux may in part be mediated by OAT4 [51], unless precluded by the carrier's 
asymmetry, in conjunction with MRP2 and MRP4, although the latter exhibit MTX affinities about  
2–3 orders of magnitude lower than determined for OAT4, with MRP2 typically displaying somewhat 
lower Km values than MRP4 (Table 2). Taken together, at low doses of MTX, the SLC22 family 
members hOAT3 and hOAT4 are likely involved in its transepithelial secretion. Under high-dose 
MTX therapy, hOAT1 may also play a significant role and could thus contribute to MTX crystalluria 
and tubular damage. 
As for the interaction between MTX and NSAIDs, increased systemic toxicity seems evident from 
common renal secretory mechanisms. In contrast, increased toxicity of MTX to the kidney under this 
condition is less easily explained. However, although hOAT3, as well as hOAT1, are highly sensitive 
to inhibition by most NSAIDs tested [50](cf. Table 1), Takeda et al. have indicated that due to the high 
plasma protein binding of NSAIDs, in vivo only indomethacin, phenylbutazone and salicylate, but not 
e.g., ibuprofen or ketoprofen, may interfere with hOAT3-dependent renal MTX secretion [51]. On the 
other hand, since the Ki values of NSAIDs for inhibition of the reduced folate carrier, at least in the rat, 
are about one to two orders of magnitude higher (70–310 µM) than those for Oat3 and Oat1 [141], 
interference of NSAIDs with proximal tubular secretion of MTX is probably even less extensive than 
assumed based on consideration of OAT3 (and OAT1) alone [28]. Thus, it would be important to Toxins 2010, 2  
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elucidate the relative contribution of RFC and OAT3/OAT1 to cellular MTX uptake and thereby 
transepithelial secretion in human renal proximal tubules at clinically relevant concentrations attained 
under both low-dose and high-dose MTX therapy. Notably, not only OAT1, 3 and 4, but also MRP2 
and MRP4 have been shown to be potently inhibited by a variety of NSAIDs, including indomethacin 
(IC50 values of 0.06 µM for MRP2 and 6 µM for MRP4) and ketoprofen (IC50 values of 1.4 and 
470 µM for MRP2 and 11.9 µM for MRP4)[52].  
However, as mentioned above, pharmacokinetic evidence indicates that MTX is transported 
birectionally in the human renal tubules. At least part of the reabsorptive flux of reduced folates, such 
as 5-methyltetrahydrofolate and MTX, appears to occur in the proximal tubule, as indicated by studies 
on apical-to-basolateral flux of 5-methyltetrahydrofolate in cultured human proximal tubule cells 
[142,143], and likely involves the proton-coupled reduced folate carrier, PCFT. hPCFT has been 
shown to be expressed in renal proximal tubule cells [144] and, when transfected into MDCK cells, is 
targeted to the apical membrane, while hRFC, consistent with its localization in mouse kidney, is 
targeted basolaterally [145]. PCFT has been shown to accept methotrexate as a substrate, even though 
its MTX transport activity appears to be low, and the affinity [146], which is highly pH-dependent, is 
not known for the mildly acidic conditions normally encountered in the proximal tubule. Moreover, to 
our knowledge it is still unknown whether NSAIDs can interfere with hPCFT-mediated reabsorption 
of MTX from the tubular fluid and thereby enhance kidney injury. 
Interestingly, however, another luminal transporter further along the renal tubule, namely 
OATP1A2, has recently been shown to transport MTX and implicated in its reabsorption [147]. 
OATP1A2 has been immunolocalized to the apical membrane of renal distal tubules [148], and its 
MTX affinity (Km 457 µM) is consistent with therapeutically induced intratubular MTX concentrations 
in this nephron segment expected to be up to 100 times higher than in plasma [147]. Although so far 
the sensitivity of OATP1A2 to NSAID inhibition has also not been reported, Oatp1a1 (also known as 
oatp1) as one of its rat homologs [149] has shown to be significantly inhibited by indomethacin 
concentrations in the micromolar range [150]. If human OATP1A2 were similarly sensitive, it appears 
possible that even low rates of OAT1-/OAT3-mediated proximal tubular secretion of indomethacin 
might suffice to achieve inhibitory levels in the distal nephron. In summary, similar to increases in 
plasma MTX concentrations induced by NSAIDs, their potentiating effect on nephrotoxicity is still 
incompletely resolved and requires consideration of both proximal tubular secretory mechanisms as 
well as potential reabsorptive pathways also in later parts of the nephron. 
4.2. Crystal-nephropathy caused by ciprofloxacin and ceftriaxone 
Ciprofloxacin crystalluria had orginally been considered an unlikely event in humans, as 
precipitation was only observed at alkaline pH values >7.3 [151]. Nevertheless, a number of cases of 
acute renal failure have been attributed to ciprofloxacin nephrolithiasis, including several more recent 
ones [152–155]. Ciprofloxacin is a widely used broad-spectrum fluoroquinolone antibiotic, which is 
among the three drugs recommended by the WHO for the treatment of dysentery in children, a prime 
cause of morbidity especially in developing countries [156]. Ciprofloxacin is preferentially 
administered orally and renal elimination accounts for ~50% under this condition, about two-thirds of 
which are the parent compound [157]. Following intravenous injection, ~60% are eliminated Toxins 2010, 2  
 
 
2068
unchanged via the kidneys. Mean serum protein binding has been determined to amount to about 40% 
[157] and is given as 20–40% by the Bayer package insert 2009, indicating that a substantial fraction 
of ciprofloxacin is likely filtered at the glomerulus. Yet, renal clearance assayed only upon intravenous 
administration greatly exceeded the creatinine clearance, depending on dosage by up to 200%, 
indicating substantial net tubular secretion [157], which is consistent with the observation that   
co-administration of the organic anion transport inhibitor probenecid significantly decreases renal 
ciprofloxacin excretion by ~60% [158]. 
One likely candidate to mediate basolateral ciprofloxacin uptake in the renal proximal tubule is 
hOAT3, which has recently been shown to be sensitive to ciprofloxacin inhibition (~60% inhibition at 
10,000-fold excess over the substrate), whereas hOAT1-mediated transport was not significantly 
affected [135]. Additional support for an involvement of Oat3, but not Oat1, was provided by the 
demonstration that expression of mouse Oat3 in CHO cells resulted in significantly (5-fold) higher 
ciprofloxacin uptake compared to controls, which was abolished in the presence of probenecid, 
whereas mouse Oat1 did not. Moreover, following injection of a single bolus of ciprofloxacin, 
significantly increased ciprofloxacin plasma concentrations were detected in Oat3 knockout relative to 
wildtype mice [135]. 
Based on one study on the ciprofloxacin resistence in mouse macrophages, MRP4 might be more 
likely than MRP2 to play a role in apical ciprofloxacin extrusion in the renal proximal tubule. It will be 
important to verify that human OAT3 and MRP4 do indeed behave similarly as their mouse 
counterparts with respect to ciprofloxacin handling, which may not necessarily be the case. In this 
context it is noteworthy that, while the rat cation transporter MATE1, expressed in the apical 
membrane of proximal tubule cells [159], has been found to be able to transport ciprofloxacin, this 
does not seem to be apply for the human MATE1 or MATE2-K, although they were potently inhibited 
by it [136,160]. Interaction of ciprofloxacin, which is zwitterionic at physiological pH [161], with at 
least some organic cation transporters also indicates, that others, like e.g., hOCT2 may also not be 
completely disregarded as potential additional renal ciprofloxacin transporters. 
There are several reports in the literature associating the third-generation cephalosporin ceftriaxone 
with nephrolithiasis—generally believed to be due to the formation of insoluble precipitates with 
calcium—especially in children, but impairment of renal function was usually not observed [162–164]. 
In isolated cases, however, ceftriaxone crystalluria has been fatal in neonates and infants, leading the 
US FDA in 2007 to recommend not using calcium-containing infusions simultaneously with 
ceftriaxone [165]. Close monitoring for kidney stone formation during ceftriaxone therapy has also 
been suggested [162]. Ceftriaxone is widely used to treat childhood infections, and is another   
WHO-recommended drug to treat dysenteria [156]. Although like other cephalosporins, ceftriaxone is 
eliminated to a significant extent (approx. 40%) via the kidneys [166,167], it differs in a substantially 
longer elimination half-life than reported for most other cephalosporins [166]. This may in part be due 
to its high serum protein binding, limiting glomerular filtration [166,167]. Nevertheless, glomerular 
filtration still accounts for about 70% of the total renal ceftriaxone clearance, while the remainder is 
mediated by probenecid-sensitive tubular secretion [167]. Important players in the proximal tubular 
handling of cephalosporin antibiotics in general have already been discussed above in the context of 
direct tubular toxicity. Toxins 2010, 2  
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As mentioned, human OAT3 expressed in HEK293 cells mediated uptake of all cephalosporins 
tested, albeit the extent substantially differed between compounds when assayed at equal 
concentrations [34]. However, while ceftriaxone was not included in this study, it exhibited a far lower 
inhibitory potency than other cephalosporins on hOAT3-mediated transport (Ki 4.39 mM) in another 
[32]. It thus appears unlikely that hOAT3 plays a significant role in ceftriaxone secretion at clinically 
relevant plasma concentrations [166,168]. hOAT1, on the other hand, appeared to be able to accept 
only a limited number of cephalosporins as substrates, which—additionally—were transported rather 
poorly, with uptake never higher than twice the control level in hOAT1-expressing HEK293 cells [34]. 
Thus, despite a similarly low Ki value determined for ceftriaxone interaction with hOAT1 as for 
cefazolin (230 µM and 180 µM, respectively)[32], hOAT1-mediated ceftriaxone transport may still be 
low or absent, as cefazolin is also not an hOAT1 substrate. hOAT2 is unlikely to play a role in renal 
ceftriaxone handling in vivo as well, given the high reported Ki value of over 6 mM [32]. Taken 
together, these data are in line with the long elimination half-life of ceftriaxone, and indicate that 
OAT-dependent basolateral ceftriaxone uptake as the first step in transtubular secretion is not an 
important mediator in ceftriaxone nephrotoxicity. It may therefore rather depend on—albeit limited—
glomerular filtration, with the possible contribution of as yet unidentified secretory pathways, 
involving MRP2 [29], and maybe MRP4, at the luminal side. 
4.3. Acyclovir-induced nephrolithiasis 
Crystal nephropathy is a well-known adverse side-effect of the antiviral drug acyclovir with its low 
solubility in urine, in particular when applied intravenously at high doses [4,66]. Acyclovir is a 
guanosine analogue widely used in the treatment of infections with members of the herpesvirus family. 
Binding of acyclovir to plasma proteins has been determined to be low, and elimination occurs to an 
average of ~65% as unchanged drug via the kidneys by glomerular filtration as well as tubular 
secretion [169]. The importance of tubular transport in renal acyclovir excretion is supported by its 
substantial inhibition when co-administered with probenecid or cimetidine [170,171]. Acyclovir has 
been shown to be a substrate of human OAT1, albeit with an affinity about one order of magnitude 
lower than the nucleotide analogues [137], possibly in part due to its lack of a negative charge. In 
contrast, neither hOAT3, nor hOAT2 or hOAT4 were able to transport acyclovir, although hOAT3 was 
sensitive to acyclovir inhibition [10,137]. Interestingly, acyclovir was also found to be transported by 
hOCT1, which is, however, only expressed to very low levels in human kidney [8,172], whereas 
hOCT2, which is strongly expressed in kidney [8,172,173], did not mediate acyclovir uptake [137]. 
Regarding apical efflux, there is no information regarding MRP2- or MRP4-mediated acyclovir 
transport. However, MRP4 overexpression has been shown to confer resistance to another guanosine 
analogue, ganciclovir [174], making MRP4 a candidate export mechanism for acyclovir into the 
tubular lumen. Although the human organic cation/proton exchangers MATE1 and MATE2-K have 
both been reported to accept acyclovir as a substrate, they do so with rather low affinity (Km values of 
2.64 and 4.32 mM, respectively)[136]. Hence, it is questionable whether they could indeed 
significantly contribute to proximal tubular acyclovir secretion at the cellular concentrations that will 
be attained at clinically relevant plasma levels in the low micromolar range [169,171,175].  Toxins 2010, 2  
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5. Concluding Remarks 
OAT family members clearly play a critical role in the renal transport of a variety of drugs with 
well-known nephrotoxic potential. Certainly, their importance might be overestimated in isolated cases 
where major alternative transport pathways may not have been identified, as exemplified by renal 
MTX handling. However, not recognizing a possible interaction of clinically relevant drugs with 
OATs, or any other transporter involved in renal xenobiotic handling, is potentially far more 
consequential. Thus, toxicity of compounds accumulated in renal proximal tubule cells by OAT1- 
and/or OAT3-mediated transport may only become apparent when (apical) extrusion is impaired. This 
could be due to polymorphisms affecting expression and/or function of the mechanism/s responsible, 
or their unanticipated inhibition by co-administered agents. It thus seems imperative for all newly 
developed drugs to be tested against any potentially interacting transport mechanism available for 
functional analysis. Clearly, transport affinity, turnover rate and sensitivity to inhibition in 
heterologous expression systems will never accurately reflect the in vivo situation, even if assayed 
under conditions resembling human serum. Yet, together with knowledge of the relative expression 
levels of different transporters and driving forces in the tissue, such tests may still give a good 
indication of, e.g., levels of cellular drug accumulation or drug interactions to be expected. Moreover, 
they may provide important clues on the parameters to be analysed in patients, when certain drugs are 
to be given, leading to more personalized and hopefully less toxic drug therapies.  
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